AI Article Synopsis
- Drug-resistant Acinetobacter baumannii is a growing concern, and this study assesses the effectiveness of eravacycline and its relationship with the RND-efflux pump system.
- The study analyzed 48 clinical isolates, revealing that 72.91% were extensively drug-resistant (XDR), with 60.41% susceptible to eravacycline.
- The findings suggest that eravacycline is a promising option for treating severe infections caused by XDR Acinetobacter, while highlighting the need for better understanding and management of antibiotic resistance.
Article Abstract
Purpose: Drug-resistant Acinetobacter baumannii is an emerging threat. This study has been conducted to observe the efficacy of eravacycline along with the RND-efflux pump system.
Methods: A cross-sectional study was done collecting 48 clinical isolates of Acinetobacter baumannii. MICs of 15 antibiotics were detected along with BMD of tigecycline and eravacycline. PCR products of drug-resistant regulatory genes were sequenced and analyzed.
Results: Of the total 48 Isolates, 35 (72.91%) were XDR and 13 (27.08%) were MDR. Out of all, 60.41% of isolates were found to be susceptible to eravacycline by BMD according to both FDA and EUCAST guidelines. A 2-fold decline of MIC50/90 was observed with the use of eravacycline compared to tigecycline. RND-efflux genes like AdeC in 30 (62.5%) isolates and Regulatory gene AdeS in 29 (60.41%) isolates were detected, explaining the existing resistance mechanism.
Conclusions: XDR Acinetobacter poses an escalating threat due to its resistance to multiple antibiotics, raising serious concerns in healthcare settings. Eravacycline is an encouraging new drug for empirical use in severe infection caused due to the same. Molecular investigation and strict antimicrobial stewardship should be followed to control the emergence, and a better understanding of mechanisms of resistance to prevent the spread of drug-resistant isolates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijmmb.2024.100565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Leech Antimicrobial Peptides, Hirunipins: Real-Time 3D Monitoring of Antimicrobial and Antibiofilm Mechanisms Using Optical Diffraction Tomography.
Adv Sci (Weinh)
January 2025
Department of Biological Sciences and Biotechnology, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.
Antimicrobial peptides (AMPs) are promising agents for treating antibiotic-resistant bacterial infections. Although discovering novel AMPs is crucial for combating multidrug-resistant bacteria and biofilm-related infections, their clinical potential relies on precise, real-time evaluation of efficacy, toxicity, and mechanisms. Optical diffraction tomography (ODT), a label-free imaging technology, enables real-time visualization of bacterial morphological changes, membrane damage, and biofilm formation over time.
View Article and Find Full Text PDFNosocomial Pneumonia in Georgia: A Study of Extended Spectrum Beta-Lactamase (ESBL)-Producing Versus Non-extended ESBL Gram-Negative Bacterial Profiles.
Cureus
December 2024
Biomedical Sciences, Georgian American University (GAU), Tbilisi, GEO.
Background: Nosocomial pneumonia is a significant healthcare challenge, particularly in the face of rising antimicrobial resistance among Gram-negative bacteria. The production of extended spectrum beta-lactamase (ESBL) exacerbates treatment complexities.
Aim: This study investigates the prevalence and resistance patterns of ESBL-producing and non-ESBL Gram-negative bacteria in nosocomial pneumonia cases in Georgian hospitals to inform antibiotic stewardship and treatment strategies.
Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.
Sci Rep
January 2025
Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Acinetobacter baumannii, an opportunistic bacterium prevalent in various environment, is a significant cause of nosocomial infections in ICUs. As the causative agent of pneumonia, septicemia, and meningitis, A. baumannii typically exhibits multidrug resistance and is associated with poor prognosis, thus led to a challenge for researchers in developing new treatment and prevention methods.
View Article and Find Full Text PDFMeasuring water pollution effects on antimicrobial resistance through explainable artificial intelligence.
Environ Pollut
January 2025
Università degli Studi di Bari Aldo Moro, Dipartimento Interateneo di Fisica M. Merlin, Bari, 70125, Italy; Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Bari, Bari, 70125, Italy.
Antimicrobial resistance refers to the ability of pathogens to develop resistance to drugs designed to eliminate them, making the infections they cause more difficult to treat and increasing the likelihood of disease diffusion and mortality. As such, antimicrobial resistance is considered as one of the most significant and universal challenges to both health and society, as well as the environment. In our research, we employ the explainable artificial intelligence paradigm to identify the factors that most affect the onset of antimicrobial resistance in diversified territorial contexts, which can vary widely from each other in terms of climatic, economic and social conditions.
View Article and Find Full Text PDFRapid Design of Combination Antimicrobial Therapy against .
Comput Chem Eng
January 2025
Department of Chemical and Biomolecular Engineering, University of Houston Cullen College of Engineering, Houston, TX 77204.
Treatment of serious bacterial infections with antimicrobial agents, such as antibiotics, is a major clinical challenge, because of growing bacterial resistance to multiple agents. Combination therapy (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!